Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should patients with osteoarthritis be treated with COX2 inhibitors rather than traditional NSAIDs?

Nature Clinical Practice Rheumatology volume 3, pages 316–317 (2007)Cite this article

Access through your institution
Buy or subscribe

boxed-textCannon CP et al. (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368: 1771–1781

Background

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kearney PM et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 332: 1302–1308

    Article  CAS  Google Scholar 

  2. Lanas A et al. (2006) Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55: 1731–1738

    Article  CAS  Google Scholar 

  3. Schnitzer TJ et al. (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364: 665–674

    Article  CAS  Google Scholar 

  4. Silverstein TJ et al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: a randomized controlled trial. JAMA 284: 1247–1255

    Article  CAS  Google Scholar 

  5. Laine L et al. (2007) Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 369: 465–473

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Murphy, Assistant Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. B Rocca is Adjunct Professor of Pharmacology at the 2nd Medical School of the University of Rome “La Sapienza”, and G Davì is Professor of Internal Medicine at the University of Chieti, Italy.,

    Bianca Rocca & Giovanni Davì

Authors
  1. Bianca Rocca
    View author publications

    Search author on:PubMed Google Scholar

  2. Giovanni Davì
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Bianca Rocca.

Ethics declarations

Competing interests

Dr Davi and Dr Rocca have received research support from the following companies/organisations: Bayer AG, Merck, Nycomed, Sanofi-Aventis, Glaxo, Servier(GD)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rocca, B., Davì, G. Should patients with osteoarthritis be treated with COX2 inhibitors rather than traditional NSAIDs?. Nat Rev Rheumatol 3, 316–317 (2007). https://doi.org/10.1038/ncprheum0480

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncprheum0480

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing